Analysts reality-check Dupixent’s ‘megabrand’ ambition
Analysts say the drug’s road to megabrand status may depend on uptake in some rather obscure disease areas.
Pipeline
Pipeline Report 2020: Drugs rising from R&D purgatory, new vaccines set to surge in coming year
Several candidates relegated to the R&D graveyard re-emerged from their tombs this year and now headline the pharma developmental slate for 2020.
Analysts: Amarin poised for huge gains if Vascepa trial comes back positive
Analysts from Jefferies predicted up to $2 billion in peak sales if Amarin’s seven-year trial data is positive.
Two drugs in the pipeline representing unique marketing challenges
Two touted products in the pipeline reflect three of medical marketing’s most profound modern-era challenges.
Analysts: J&J doesn’t need to worry about Sun Pharma’s prostate cancer drug
Sun Pharma’s branded prostate cancer treatment Yonsa just received FDA approval.
Five things for pharma marketers to know: Thursday, February 22, 2018
Novo Nordisk diabetes pill delivers in late-stage trial; Gilead partners with Sangamo on engineered cell therapies; Study finds antidepressants work, though with varying results.
Five things for pharma marketers to know: Wednesday, February 21, 2018
AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.
Flexion’s pivot proves pain-free
Clayman says the company’s next 18 months are all about Zilretta, with further pipeline construction next up.
Five things for pharma marketers to know: Friday, January 19, 2018
Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit
Five things for pharma marketers to know: Friday, January 5, 2018
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
